|
所属 |
高齢者医療先端研究センター |
学位論文 【 表示 ／ 非表示 】
-
Low Plasma Concentration of Gefitinib in Patients with EGFR Exon 21 L858R Point Mutations Shortens Progression-Free Survival
Yuji Okuda, Kazuhiro Sato, Kazuhisa Sudo, Yukiyasu Hasegawa, Mariko Asano, Hajime Miura, Masahide Takeda, Masaaki Sano, Hiroyuki Watanabe, Hiroyuki Kobayashi, Takenori Niioka, Masatomo Miura, Hiroshi Ito
Cancer Chemotherapy and Pharmacology. 2018年03月
国内共著
研究等業績 【 表示 ／ 非表示 】
-
Yuji Okuda, Kazuhiro Sato, Mariko Asano, Kentaroh Kudoh, Eiki Omoto, Yuka Izumiya, Sho Sakamoto, Masahide Takeda, Tatsunori Shimizu, Hidetaka Ota, Hirokazu Kurokawa, Yoshihiro Minamiya, Katsutoshi Nakayama
Geriatrics & gerontology international ( Geriatrics and Gerontology International ) 23 ( 8 ) 622 - 627 2023年07月
研究論文（学術雑誌）
AIM: Akita Prefecture has the largest proportion of older inhabitants and the highest cancer mortality rate in Japan. Lung cancer is one of the biggest killers, and early detection is critical. Chest X-ray examinations are the main screening method for lung cancer; however, the COVID-19 pandemic has affected the screening system. Here, we evaluate how COVID-19 has affected lung cancer screening in Akita Prefecture. METHODS: Using the Akita General Health Corporation database, the average annual number of chest X-ray screening tests, close examinations and lung cancer diagnoses (stratified by sex and age) was evaluated during 2016-2019, and compared with the 2020 values. Furthermore, data on lung cancer registrations from 2018 to 2020 were obtained from the Collaborative Akita Prefecture Hospital-Based Cancer Registration System and analyzed. RESULTS: The average annual number of screening tests, close examinations and lung cancer diagnoses declined (by >50%) between 2016 to 2019 and 2020, especially among older people (aged ≥65 years). Furthermore, by stage, the number of patients with early-stage lung cancer (stage 0-I) decreased, and the number with advanced-stage cancer (stage IV) increased. CONCLUSIONS: The COVID-19 pandemic reduced lung cancer screening participation, especially among the older adult population in Akita Prefecture, resulting in a decrease in lung cancer diagnoses through screening. This might have reduced the number of early-stage cancer registrations. It is necessary to improve health education among the public regarding the importance of chest X-ray screening. Geriatr Gerontol Int 2023; ••: ••-••.
-
Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
Kazuhisa Sudo, Kazuhiro Sato, Sho Sakamoto, Yukiyasu Hasegawa, Mariko Asano, Yuji Okuda, Masahide Takeda, Masaaki Sano, Hiroyuki Watanabe, Takanobu Shioya, Hiroshi Ito
Anticancer research 37 ( 10 ) 5565 - 5571 2017年10月
研究論文（学術雑誌）
BACKGROUND/AIM: To investigate the association between the number of circulating endothelial progenitor cells (EPCs) in non-squamous non-small cell lung cancer (NSCLC) and disease outcome, in combination chemotherapy with and without bevacizumab. MATERIALS AND METHODS: We retrospectively identified 25 non-squamous NSCLC cases, and divided them into high-EPC and low-EPC groups. Within each group, we compared disease outcomes, with or without the administration of bevacizumab. RESULTS: In the high-EPC group, chemotherapy with bevacizumab produced a significantly higher tumor reduction rate and objective response rate, with significantly longer progression-free survival, compared to chemotherapy without bevacizumab (p<0.001, p=0.010, and p<0.001, respectively). However, in the low-EPC group, there were no significant differences in disease outcomes in groups with versus those without bevacizumab. CONCLUSION: The number of EPCs may be a useful biomarker to guide decision-making in the use of bevacizumab in non-squamous NSCLC.
-
びまん性の肺動静脈奇形に対し、経カテーテルコイル塞栓 術を施行した４症例
奥田 佑道、佐藤 一洋、坂本 祥、須藤 和久、長谷川 幸保、浅野 真理子、竹田 正秀、飯野 健二、佐野 正明、塩谷 隆信、橋本 学、渡邊 博之
学内誌「秋田医学」 2018年03月 [査読有り]
研究論文（大学，研究機関紀要） 国内共著
-
Sakamoto S.
Current Problems in Cancer: Case Reports ( Current Problems in Cancer: Case Reports ) 10 2023年06月
-
秋田県における新型コロナウイルス感染症の流行が高齢者の肺がん検診に与えた影響について
奥田 佑道, 浅野 真理子, 佐藤 一洋, 大本 瑛己, 坂本 祥, 竹田 正秀, 清水 辰徳, 大田 秀隆, 中山 勝敏
日本老年医学会雑誌 ( (一社)日本老年医学会 ) 60 ( Suppl. ) 182 - 182 2023年05月
-
Yokota H.
Cancer Chemotherapy and Pharmacology ( Cancer Chemotherapy and Pharmacology ) 92 ( 4 ) 315 - 324 2023年
-
Yokota H.
Investigational New Drugs ( Investigational New Drugs ) 40 ( 6 ) 1254 - 1262 2022年12月
The effects of polymorphisms in CYP3A4 (20230G > A), CYP3A5 (6986A > G), ABCB1 (1236C > T, 2677G > T/A, 3435C > T), ABCG2 (421C > A), and ABCC2 (-24C > T) on the area under the concentration-time curve (AUC) of osimertinib in 23 patients with non-small cell lung cancer were investigated. Blood sampling was performed just prior to and at 1, 2, 4, 6, 8, 12, and 24 h after osimertinib administration at the steady-state on day 15 after beginning therapy. The osimertinib AUC0-24 was significantly correlated with age (P = 0.038), serum albumin (P = 0.002), and serum creatinine (P = 0.012). Additionally, there were significant differences in the AUC0-24 of osimertinib among the groups administered vonoprazan, histamine 2-receptor antagonists or esomeprazole, and no acid suppressants (P = 0.021). By contrast, there were no significant differences in the AUC0-24 of osimertinib between genotypes of CYP3A4/5 or ABC transporters. Furthermore, there were no significant differences in the AUC0-24 of osimertinib between patients with diarrhea, skin rash, or hepatotoxicity and those without these conditions. In multivariate analysis, only serum albumin value was an independent factor predicting the AUC0-24 of osimertinib. Analysis of CYP3A4/5 and ABC transporter polymorphisms before osimertinib therapy may not predict the efficacy or side effects of osimertinib. The lower serum albumin values were associated with an increase in the AUC0-24 of osimertinib; however, further studies are needed to assess the factors contributing to the interindividual variability of osimertinib pharmacokinetics.
-
オシメルチニブによる薬剤性肺障害が疑われた高齢者肺癌の1例
浅野 真理子, 佐藤 一洋, 坂本 祥, 奥田 佑道, 竹田 正秀, 佐野 正明, 横田 隼人, 三浦 昌朋, 大田 秀隆, 中山 勝敏
日本老年医学会雑誌 ( (一社)日本老年医学会 ) 59 ( 4 ) 575 - 575 2022年10月